HealthQuill Alzheimer's Disease
The US drug regulator has approved changes in the prescription of Eli Lilly’s drug Kisunla for treating adults with early Alzheimer’s disease, including those with mild memory problems or mild dementia.
Drugs Health Pharma

FDA permits slow dosing of Eli Lilly’s Alzheimer’s drug Kisunla

HQ Team July 9, 2025: The US drug regulator has approved changes in the prescription of Eli Lilly’s drug Kisunla for treating adults.

Read More
Scientists can tell how fast or gracefully you are ageing from a single magnetic resonance image of your brain, according to researchers at Duke University.
Health Medical Research

Duke researchers’ tool helps know how fast you are ageing, future diseases

HQ Team July 7, 2025: Scientists can tell how fast or gracefully you are ageing from a single magnetic resonance image of your.

Read More
Stanford University, along with other researchers, has developed a set of gene delivery systems that can reach different neural cell types in the human brain and spinal cord with exceptional accuracy — a tool which may lead to new gene therapies to treat Parkinson’s, Alzheimer’s and neurogenerative diseases.
Drugs Health Research

Scientists make gene ‘truck’ to unload genetic package in brain, spine

HQ Team May 30, 2025: Stanford University, along with other researchers, has developed a set of gene delivery systems that can reach different.

Read More
Sanofi SA will acquire Vigil Neuroscience, Inc., a publicly traded clinical-stage biotechnology company focused on developing novel therapies for neurodegenerative diseases, for $470 million.
Drugs Health Pharma

France’s Sanofi SA to acquire US-based Vigil Neuroscience for $470 million 

HQ Team May 22, 2025: Sanofi SA will acquire Vigil Neuroscience, Inc., a publicly traded clinical-stage biotechnology company focused on developing novel therapies.

Read More
The US Food and Drug Administration has granted marketing access to Fujirebio Diagnostics, Inc.’s blood test to diagnose Alzheimer’s disease, the first such approval in the country.
Drugs Health Pharma

Simple blood test to detect Alzheimer’s disease gets US regulator’s nod

HQ Team May 18, 2025: The US Food and Drug Administration has granted marketing access to Fujirebio Diagnostics, Inc.’s blood test to diagnose.

Read More
Billionaire Bill Gates will donate more than $200 billion over the next two decades to prevent newborn child and maternal deaths, combat infectious diseases, Alzheimer’s, and close down the Gates Foundation on December 31, 2045.
Drugs Health Medical

Gates Foundation to shut in 2045, pledges $200 billion in next 20 years

HQ Team May 8, 2025: Billionaire Bill Gates will donate more than $200 billion over the next two decades to prevent newborn child.

Read More
Nuravax Inc. and its partner, the Institute for Molecular Medicine, have received a $3 million grant from the National Institutes of Health to advance its Alzheimer’s vaccine to human trials.
Drugs Health Pharma

Nuravax’s Alzheimer’s vaccine gets $3m grant to enter human trials

HQ Team May 5, 2025: Nuravax Inc. and its partner, the Institute for Molecular Medicine, have received a $3 million grant from the.

Read More
Eisai Co., Ltd. and Biogen Inc.’s drug to treat Alzheimer’s disease got marketing authorisation in the European Union, according to a joint statement from the companies.
Drugs Health Pharma

Eisai Co, Biogen Inc.’s Alzheimer’s drug gets EU’s marketing approval

HQ Team April 16, 2025: Eisai Co., Ltd. and Biogen Inc.’s drug to treat Alzheimer’s disease got marketing authorisation in the European Union,.

Read More
US adults who will develop dementia every year will rise to one million in 2060 from 514,000 in 2020, according to a study published in Nature Medicine.
Health

Semaglutide may combat Alzheimer’s by reducing brain inflammation:Study

HQ Team March 21, 2025: A study from China adds to mounting evidence that semaglutide—a medication widely used for type 2 diabetes (Ozempic).

Read More
Tau proteins in brain neurons can form neurofibrillary tangles, which are a hallmark of Alzheimer's disease, and these abnormal proteins also accumulate in the dying cells in the retina of the eyes of the patients with the condition, investigators at Cedars-Sinai Medical Center found.
Health Pharma Research

Abnormal protein accumulation in patient’s eyes linked to Alzheimer’s

HQ Team March 4, 2025: Tau proteins in brain neurons can form neurofibrillary tangles, which are a hallmark of Alzheimer’s disease, and these.

Read More